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ABSTRACT
Objectives: Palliative chemotherapy is routinely given
to patients diagnosed with locally advanced or
metastatic oesophagogastric (O-G) cancer. We examine
which patients with O-G cancer in England receive
palliative chemotherapy, and identify factors associated
with treatment completion.
Design: A prospective population-based observational
study.
Setting: All English National Health Service (NHS)
trusts diagnosing patients with O-G cancer.
Participants: Data were prospectively collected on
patients diagnosed with invasive epithelial cancer of
the oesophagus or stomach between 1 October 2007
and 30 June 2009 in English NHS hospitals, and those
who had palliative treatment intent.
Outcome measure: We calculated the proportion of
patients with different characteristics (eg, age, sex,
stage at diagnosis, performance status) starting
palliative chemotherapy. Multiple logistic regression
was used to identify characteristics associated with
non-completion of chemotherapy.
Results: There were 9768 patients in the study whose
treatment intent was palliative. Among these, 2313
(24%) received palliative chemotherapy. It was received
by 51% of patients aged under 55 years but only 9%
of patients aged 75 years or over. Overall, 917 patients
(53%) completed their treatment among the 1741
patients for whom information on treatment completion
was recorded. Treatment completion ranged from
50–60% for patients with good performance status but
was under 35% for patients aged 55 years or older
with poor performance status. Treatment completion
was not associated with site of cancer, pretreatment
stage, sex, comorbidities or histology.
Conclusions: Completion rates of palliative
chemotherapy in patients with O-G cancer are low and
elderly patients with poor performance status are very
unlikely to complete a palliative chemotherapy treatment.
Clinicians and patients should consider this information
when balancing potential (survival) benefits, toxicity of
treatment and its effect on quality of life.
INTRODUCTION
Treatment decision-making regarding pallia-
tive chemotherapy is complex. Patients and
oncologists need to balance the potential
beneﬁt of increased survival against the risk
of toxicity and its effect on quality of life.
Over-optimistic assessments of treatment
response and patients’ ability to tolerate it
could be associated with patients who start
palliative chemotherapy and fail to complete
the planned treatment, but there is little
information on how often this occurs in
practice.
This is of particular relevance in the
context of oesophagogastric (O-G) cancer, a
condition with poor prognosis and for which
experimental evidence on palliative treat-
ment is limited. O-G cancer is the ﬁfth most
common cancer and third most common
cause of death from cancer in the UK. About
17 000 patients are diagnosed every year in
the UK and approximately 12 500 deaths are
registered per year.1 2 Owing to the late
onset of symptoms and diagnosis, only 35%
Strengths and limitations of this study
▪ We examined completion of palliative chemother-
apy among patients with oesophagogastric (O-G)
cancer.
▪ Of 9768 palliative patients with O-G cancer in England,
2313 (24%) received palliative chemotherapy.
▪ Treatment completion rate was 53%, and was
lower in older patients and patients with low per-
formance status.
▪ Elderly patients with poor performance status are
unlikely to complete palliative chemotherapy.
▪ Clinicians and patients need to balance survival
benefits, quality of life and treatment toxicity.
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of patients are suitable for treatment with curative intent
and more than half of all patients die within the year of
diagnosis.3–5 To prolong survival and improve quality of
life, palliative chemotherapy is given to patients with
locally advanced or metastatic cancer.6 7
In the UK, O-G cancer therapy was inﬂuenced by the
phase 3 randomised controlled trial (RCT) comparing
epirubicin, cisplatin and infusion 5-ﬂuorouracil (5-FU;
ECF) with mitomycin, cisplatin and infusion 5-FU in
patients with oesophageal or gastric tumours.8 This
reported median survival times of 8–9 months for both
arms, and ECF became the accepted standard. Recently,
the REAL2 trial demonstrated epirubicin, oxaliplatin
and capecitabine to be an alternative to ECF among
patients with O-G cancer.9 However, for patients with
metastatic oesophageal cancer, there is uncertainty
about the median survival of patients on best supportive
care alone, and a Cochrane review failed to demonstrate
a survival beneﬁt of palliative chemotherapy.10 The
authors note that this “is in sharp contrast to the
extended application of palliative chemotherapy in prac-
tice.”10 The evidence of beneﬁt is stronger for patients
with gastric cancer. A recent meta-analysis found that
palliative chemotherapy resulted in substantially
improved survival compared with supportive care
(HR=0.37; 95% CI 0.24 to 0.55), although its use needs
to be balanced with the toxicity of the treatment.11
A limitation of the current evidence is the lack of
outcome information for different patient groups.
Various prognostic models for survival among patients
receiving palliative chemotherapy have been developed
and suggest that survival is worse for patients with poor
performance status and presence of liver/peritoneal
metastases.12 13 However, these have not consistently
included tumour site, histology, comorbidities, sex or
age. This may reﬂect their development using trial data
sets, and that patients of very old age or poor perform-
ance status are under-represented in clinical trials.14
Recent European Society for Medical Oncology (ESMO)
guidelines for patients with gastric cancer recommend
that organ function, performance status and comorbid-
ities be considered, and that age alone is not a contra-
indication.15 The ESMO guideline for patients with
oesophageal cancer recommended that palliative
chemotherapy should be considered for patients with
adenocarcinoma who have a good performance status.16
It is unknown how this evidence from controlled trials
translates into routine clinical practice, and how studies
on routine practice can help inform clinical decision-
making. There has been a long-standing debate regard-
ing the evidence generated by RCTs and observational
studies, respectively. While RCTs are considered to be
the gold standard to generate evidence for clinical
decision-making, the contributions of observational
studies can be signiﬁcant, in particular in situations in
which RCTs are unnecessary, inappropriate, impossible
or inadequate.17 The average results of RCTs and well
conducted observational studies may be remarkably
similar and observational studies do not necessarily, as
was previously assumed, overestimate the magnitude of
treatment effects.18 19 Moreover, observational studies
are less prone to heterogeneity in results than RCTs due
to the broader representation of the population at risk
and the less restrictive inclusion and exclusion criteria
of RCTs (age and comorbidities), making them more
representative of clinical practice.
In this study, we contribute to this debate by addres-
sing the routine clinical practice of palliative chemother-
apy among patients with O-G cancer. This information,
based on a national prospective cohort study, is of par-
ticular relevance to inform medical decision-making and
patient choice as it is not subject to the strict exclusion
criteria that are applied in RCTs. Speciﬁcally, we
describe the characteristics of patients with O-G cancer
who received palliative chemotherapy in England, report
on the rate of treatment completion and identify patient
factors associated with treatment completion.
MATERIAL AND METHODS
The National Oesophago-Gastric Cancer Audit
(NOGCA) captured information on treatment patterns
and outcomes on adult patients diagnosed with invasive
epithelial cancer of the oesophagus or stomach between
1 October 2007 and 30 June 2009. It covered the
process of diagnosis, staging and treatment planning as
well as the surgical, oncological and endoscopic therap-
ies delivered. Data on patients treated in English
National Health Service (NHS) trusts (acute hospital
organisations) were collected prospectively by hospital
staff and submitted via a secure web-based tool to a
central database. Details on rationale, data collection
procedures and results of the audit have been reported
elsewhere.3 4
Data from the NOGCA are collected and analysed by
the Royal College of Surgeons of England and the Health
and Social Care Information Centre, supported through
a grant from the Healthcare Quality Improvement
Partnership. Permission for this analysis was granted by
the NOGCA Clinical Reference Group. Data can be
accessed through formal data accession request and
approval by the Clinical Reference Group. The study was
exempt from the UK National Research Ethics
Committee approval as it involved analysis of data for
service evaluation. Section 251 approval was obtained for
the collection of the personal health data from the Ethics
and Conﬁdentiality Committee.
Patient characteristics and study variables
The study included all patients with a palliative treat-
ment intent. Information was collected on patient
characteristics such as age, sex, social deprivation index,
tumour site, pretreatment stage, pretreatment histo-
logical diagnosis, performance status (Eastern
Cooperative Oncology Group score), and comorbid-
ities.20 21 We grouped the site of cancer into two
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categories: oesophageal (oesophageal squamous cell car-
cinoma, upper or middle adenocarcinoma and lower or
Siewert I adenocarcinoma) and gastric (gastrooesopha-
geal junction Siewert II or III, and stomach).10 11 The
audit collected information on the start of palliative
chemotherapy, oncological treatment intent and
whether patients completed the palliative chemotherapy
regimen. The audit did not collect information on the
regimen used.
The study captured treatment completion by adopting
the data item from the National Cancer Dataset.22 The
item captured whether treatment was delivered as
planned or the reason for a change from this. Reasons
for non-completion included: patient died, progressive
disease during chemotherapy, acute toxicity, organisa-
tional problems and patient choice. This information
was recorded by local clinicians and was calculated for
ﬁrst-line treatment only. As this is a national study, the
number of participants was not calculated using a
formal sample size calculation.
Statistical analysis
The study examined the proportion of patients with pal-
liative treatment intent who received palliative chemo-
therapy, and the rate of treatment completion among
patients receiving chemotherapy. These proportions
were calculated for England overall, and for patients
with various characteristics including age, sex, tumour
site, pretreatment stage and performance status. The
statistical signiﬁcance of differences between individual
characteristics were tested using χ2 tests.
We estimated the association between patient
characteristics and the likelihood of treatment comple-
tion using multiple logistic regression with robust SEs.23
For two variables with missing data, we imputed values
using multiple imputation by chained equation techni-
ques by ﬁrst creating multiple (10) copies of the data set
and then ﬁtting multiple logistic regression models to
the imputed data sets. Variables in the imputation
model included sex, age, site of cancer, diagnosis, pre-
treatment stage, performance status, comorbidities,
deprivation and treatment completion. As recom-
mended, imputed data on treatment completion was
excluded from the regression model evaluating the asso-
ciation between patient characteristics and treatment
completion.24
Finally, sensitivity analysis was performed to examine
the effect of the data completion rate. First, we assessed
how completion rates varied between NHS trusts with
different levels of missing outcome data. Second, we
examined two hypothetical scenarios in which (A) all
patients with missing treatment outcome completed
treatment and (B) none of the patients with missing
treatment outcome completed treatment.
All analyses were performed in Stata V.11. All statistical
tests are two-sided and p values lower than 0.05 were
considered to show a signiﬁcant result.
RESULTS
English NHS trusts submitted data on 16 264 adult
patients diagnosed with O-G cancer between 1 October
2007 and 30 June 2009 to the Audit. Of the 9768 patients
with a palliative treatment intent, 2313 (23.7%) under-
went palliative chemotherapy (table 1). This treatment
was more commonly used among younger patients and
those with good performance status. Nonetheless,
around 10% of patients aged 75 years or over, or who had
a performance status of 2 or worse, received palliative
chemotherapy. A lower proportion of women than men
received palliative chemotherapy (17.4% vs 27.1%; χ2
test, p<0.001). Women were also less likely to undergo
curative resection (31.5% vs 36.5%, p<0.001) and were
more likely to be managed on a best-supportive-care
pathway (30.5% vs 23.9%, p<0.001). However, the differ-
ences for the proportion of women receiving palliative
chemotherapy become non-signiﬁcant after adjusting for
case-mix, due to the effect of age and performance
status.
Information on treatment completion was available
for 1741 (75%) of the 2313 patients initiating chemo-
therapy. Among patients with known status of treatment
completion, 917 (52.7%) completed the chemotherapy,
while 244 (14%) died before all treatment was received.
Treatment was stopped because of disease progression,
toxicity of treatment or technical problems for 274
(15.7%), 174 (10%) and 3 patients, respectively. There
were 129 (7.4%) patients who chose to stop treatment.
Comparing the characteristics of patients with known
and unknown treatment outcome, we found no
signiﬁcant differences with regard to sex, site of tumour,
histology, pretreatment stage and performance status.
A higher proportion of patients with unknown treatment
outcome were missing information on pretreatment
stage and performance status, and these patients had
slightly fewer comorbidities recorded (online supple-
mentary table S1).
The relationship between individual patient character-
istics and the proportion of patients completing pallia-
tive chemotherapy is summarised in table 2. The rate of
completion did not differ between men and women, or
between oesophageal and gastric tumours, but the rate
fell as the age of patients increased. Rates of completion
among patients also decreased with lower performance
status, number of comorbidities and the level of social
deprivation.
Table 3 shows the results of the regression models for
associations between patient characteristics and comple-
tion of chemotherapy. The ﬁrst column presents the ORs
for treatment completion in a data set in which informa-
tion on all covariates was complete. The results are pre-
sented for each of the covariates individually, and then
adjusted for all remaining variables reported in the table.
After adjustment, patient age, performance status and
level of deprivation remained independent predictors of
the completion of chemotherapy. The second column pre-
sents the same data using the imputed data for all patients
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for whom the outcome (treatment completion) was
known. Both data sets produced similar results.
The estimated rates of completion derived from the
model suggested that the degree to which completion
rates changed across the age groups varied among the
different performance status scores (ﬁgure 1). However,
a formal test for interaction between age and perform-
ance status proved to have insufﬁcient statistical power
to demonstrate this.
We further assessed the robustness of the estimates for
treatment completion by conducting the two sensitivity
analyses.
First, the overall treatment completion rate was not
associated with the amount of missing data within NHS
trusts: The rate was 49.2% for NHS trusts with no missing
data (95% CI 44.8% to 53.6%), 51.1% for trusts with
10–20% missing (47.5% to 54.7%), 50.5% for trusts with
20–30% missing (45.4% to 55.6%) and 53% for trusts
with more than 30% missing data (46.8% to 55.9%).
Second, assuming that all patients with missing treat-
ment outcome had completed their treatment gave an
upper limit on the overall completion rate of 64.4%.
Assuming that none of the patients with missing treatment
outcome had completed their treatment gave a lower limit
of 39.6%. We note that the true treatment completion rate
is likely to be less than the 52.7% observed because
patients for whom treatment completion was not available
had worse performance status on average.
DISCUSSION
Main findings of the study
This study gives a national picture for the use of pallia-
tive chemotherapy among English patients with O-G
Table 1 Patient selection for palliative chemotherapy among all patients with palliative treatment intent
Patients (%) with palliative
treatment intent
Patients (%) undergoing
palliative chemotherapy
All patients n=9768 n=2313 23.7
Age
Under 55 670 (6.9) 344 51.3
55–64 1344 (13.8) 626 46.6
65–74 2437 (24.9) 853 35.0
75 and over 5317 (54.4) 490 9.2
Gender
Female 3429 (35.1) 596 17.4
Male 6339 (64.9) 1717 27.1
Index of multiple deprivation
1 (least) 1806 (18.5) 502 27.8
2 1832 (18.8) 471 25.7
3 2016 (20.6) 490 24.3
4 1967 (20.1) 400 20.3
5 (most) 2147 (22.0) 450 21.0
Tumour
Oesophagus 5686 (58.2) 1286 22.6
Stomach 4082 (41.8) 1027 25.2
Diagnosis (histology)
Adenocarcinoma 7411 (75.9) 1884 25.4
Squamous cell 1661 (17.0) 304 18.3
Other 696 ( 7.1) 125 18.0
Pretreatment stage
1 or 2 892 ( 9.1) 83 9.3
3 1127 (11.5) 239 21.2
4 3896 (39.9) 1377 35.3
Missing 3853 (39.5) 614 15.9
ECOG/WHO performance status
0 no restrictions 1413 (14.5) 622 44.0
1 restricted in strenuous activities 1835 (18.8) 620 33.8
2 unable to work or worse 3474 (35.6) 326 9.4
Missing 3046 (31.2) 745 24.5
Comorbidities
None 5317 (54.4) 1551 29.2
1 2638 (27.0) 542 20.5
2 or more 1813 (18.6) 220 12.1
ECOG, Eastern Cooperative Oncology Group.
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cancer, and the proportion of patients who complete
their prescribed therapy. Palliative chemotherapy was
received by 23.7% of patients with palliative treatment
intent, but was more commonly received by younger
patients and those with good performance status. A sub-
stantially lower proportion of women than men received
palliative chemotherapy; however, this can be partly
explained by the effect of age (women were on average
5 years older at diagnosis) and other case-mix variables
such as TNM classiﬁcation stage (advanced disease).
Residual differences may be explained by patient choice
and preferences for a less aggressive approach to pallia-
tive care among women; however, data were not available
to test these assumptions statistically.
The overall rate of treatment completion was 52.7%.
Information on the drug regimen for chemotherapy was
not available for this study, but, assuming that the
treatment selected was the most appropriate for the
patient, it suggests that a substantial proportion of
patients are not completing palliative chemotherapy,
and raises questions about whether it is possible to
improve the process of decision-making for patients and
clinicians.
Higher completion rates were obtained in patients
who were younger, had a good performance status and
were from less deprived groups. Performance status is an
established risk factor for predicting survival after pallia-
tive chemotherapy, and the ESMO guidelines for
patients with oesophageal or gastric cancer recommend
that patients undergoing treatment have good perform-
ance status.12 13 15 16 Consistent with best practice guide-
lines, neither guideline recommends age as a factor to
consider in treatment decisions, but our results suggest
that age is associated with a lower completion of
Table 2 Relationship between patient characteristics and completion of chemotherapy
Patients (%) with
known outcome*
Patients (%) who
completed treatment†
p Valuen=1741 100 n=917 52.7
Age
Under 55 268 (15.4) 160 59.7
55–64 479 (27.5) 273 57.0 <0.001
65–74 634 (36.4) 325 51.3
75 and over 360 (20.7) 159 44.2
Gender
Female 454 (26.1) 244 53.7 0.594
Male 1287 (73.9) 673 52.3
Index of multiple deprivation
1 (least) 393 (22.6) 229 58.3
2 363 (20.9) 203 55.9
3 357 (20.5) 183 51.3 0.008
4 311 (17.9) 158 50.8
5 (most) 317 (18.2) 144 45.4
Tumour
Oesophagus 969 (55.7) 505 52.1 0.603
Stomach 772 (44.3) 412 55.4
Diagnosis
Adenocarcinoma 1418 (81.5) 756 53.3
Squamous cell 230 (13.2) 113 49.1 0.488
Other 93 ( 5.3) 48 51.6
Pretreatment stage
1 or 2 65 ( 3.7) 37 56.9
3 197 (11.3) 105 53.3 0.822
4 1088 (62.5) 576 52.9
Missing 391 (22.5) 199 50.9
ECOG/WHO performance status
0 no restrictions 497 (28.6) 297 59.8
1 restricted in strenuous activities 524 (30.1) 278 53.1 <0.001
2 unable to work or worse 271 (15.6) 86 31.7
Missing 449 (25.8) 256 57.0
Comorbidities
None 1098 (63.1) 599 54.6
1 461 (26.5) 236 51.2 0.045
2 or more 182 (10.4) 82 45.1
*Column percentages.
†Row percentages.
ECOG, Eastern Cooperative Oncology Group.
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treatment.25 Moreover, we observed that patients of
older age are less likely to receive palliative chemother-
apy. This clearly suggests that age is an important factor
in decisions about treatment, although it is unclear
whether this is driven by clinician or patient preferences,
or both. Further research is required to understand
these relationships, and how advice can be better tai-
lored to patient age. Our ﬁnding that the completion
rate of chemotherapy was not linked to tumour site, hist-
ology or sex is consistent with previous research.12–14
Comparison with other studies and implications of results
We were unable to identify other large prospective
studies assessing completion of palliative chemotherapy
for O-G cancer in actual practice. Data on toxicity of pal-
liative chemotherapy treatment are usually collected
alongside experimental studies.8 26 However, the classiﬁ-
cation and grading of toxicity is not always systematic
and, based on our data, only accounts for one-ﬁfth of
those who did not complete treatment.27 Moreover,
experimental studies are often small and not powered to
identify different factors associated with completion.10 11
They may also lack generalisability because patients of
older age and lower performance status are typically
under-represented.14
There has been some observational research on com-
pletion rates for other types of cancer, albeit not for pal-
liative therapy. For example, US studies performed on
the basis of the Surveillance, Epidemiology, and End
Results (SEER) Medicare database suggest that comple-
tion rates of adjuvant chemotherapy in patients with epi-
thelial ovarian cancer approximate 46.5%; age and more
than two comorbidities were identiﬁed as signiﬁcant pre-
dictors.28 Using the same data source, the overall com-
pletion rate of adjuvant chemotherapy among patients
with colon cancer was found to be 62.2%, but this
varied by age, marital status and level of comorbidity.29
While it is recognised that decisions regarding whether
Table 3 Results of logistic regression models for associations between patient characteristics and completion of
chemotherapy
Analysis of cases with complete data on
patient factors (n=1291)
Analysis using all patients
with known outcomes (n=1741)
Unadjusted OR Adjusted OR* (95% CI) Adjusted OR (95% CI)*
Age
Under 55 1 1 1
55–64 0.89 0.89 (0.62 to 1.27) 0.90 (0.66 to 1.23)
65–74 0.71 0.75 (0.54 to 1.04) 0.75 (0.55 to 1.01)
75 and over 0.53 0.64 (0.43 to 0.97) 0.60 (0.43 to 0.84)
Gender
Female 1 1 1
Male 0.94 1.01 (0.75 to 1.37) 0.91 (0.72 to 1.14)
Index of multiple deprivation
1 (least) 1 1 1
2 0.91 0.96 (0.64 to 1.43) 0.93 (0.69 to 1.25)
3 0.75 0.71 (0.46 to 1.11) 0.78 (0.58 to 1.05)
4 0.74 0.72 (0.46 to 1.13) 0.78 (0.57 to 1.07)
5 (most) 0.60 0.60 (0.40 to 0.90) 0.66 (0.49 to 0.91)
Tumour
Oesophagus 1 1 1
Stomach 1.05 1.08 (0.85 to 1.37) 1.10 (0.89 to 1.36)
Diagnosis
Adenocarcinoma 1 1 1
Squamous cell 0.85 0.85 (0.59 to 1.20) 0.81 (0.59 to 1.11)
Other 0.93 0.96 (0.54 to 1.70) 0.97 (0.63 to 1.51)
Pretreatment stage
1 or 2 1.17 1.58 (0.58 to 4.27) 1.27 (0.67 to 2.39)
3 1.01 1.20 (0.52 to 2.74) 1.20 (0.83 to 1.73)
4 1 1 1
ECOG/WHO performance status
0 no restrictions 1 1 1
1 restricted in strenuous activities 0.76 0.83 (0.62 to 1.10) 0.75 (0.58 to 0.96)
2 unable to work or worse 0.31 0.37 (0.26 to 0.53) 0.34 (0.25 to 0.46)
Comorbidities
None 1 1 1
1 0.87 0.94 (0.71 to 1.25) 0.94 (0.75 to 1.18)
2 or more 0.68 0.80 (0.53 to 1.20) 0.78 (0.56 to 1.09)
*Adjusted for the remaining variables.
ECOG, Eastern Cooperative Oncology Group.
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to continue treatment will be made differently in the
curative and palliative setting, the factors associated with
non-completion are similar to our study, suggesting that
factors associated with appropriate patient selection for
chemotherapy may also be similar across treatment
settings.
Medical decision-making regarding palliative chemo-
therapy is complex and involves balancing clinical risk
factors, potential beneﬁts (including predicting survival)
and harms, patient preferences and the probability of
treatment completion. Palliative chemotherapy may
prolong survival and quality of life ‘on average’, but this
patient population will also contain people who respond
and tolerate treatment poorly. While we do not have
detailed quality of life analyses as part of this data set, it
is highly likely that a substantial proportion of patients
will not have beneﬁted from treatment due to unaccept-
able toxicity, disease progression or death and that clini-
cians would not have chosen to treat these patients if
these outcomes could have been predicted.
Enriching patient beneﬁt populations is the fundamen-
tal concept behind personalised or stratiﬁed oncology.30
As well as ﬁnding biological factors or biomarkers that
determine patient outcome and response to treatment,
there is also a need to analyse factors associated with
patient selection, such as age, performance status, extent
of disease and patient choice. Lack of treatment comple-
tion may reﬂect an overly optimistic assessment of patients’
likelihood to complete and beneﬁt from treatment, or a
preference of treatment over best supportive care among
patients despite poor prognostic factors, or a lack of
adequate institutional and social support services.31 32
Further studies should address the factors associated
with treatment completion in more depth and assess the
beneﬁts of palliative chemotherapy not only in terms of
survival but also in terms of health-related quality of life.
The latter is a key issue as at present it is unclear how non-
completion of therapy is related to potential beneﬁts of
therapy. In other words, an incomplete palliative chemo-
therapy treatment stopped due to patient choice may still
be associated with symptom relief and increased survival.
However, non-completion may also be due to acute toxicity
or death and in this case, given the short life expectancy of
patients with O-G cancer on a palliative care pathway, may
offer little beneﬁt and in fact expose patients and their
families to unnecessary distress. Research should also
focus on whether treatment completion is associated with
healthcare utilisation near end of life. Initiation of pallia-
tive chemotherapy in the last month of life is likely to
reﬂect overtreatment of little beneﬁt to patients.
Study strengths and limitations
The study was based on a large, prospective sample of
patients diagnosed in 137 English NHS trusts, 89% of all
English NHS trusts providing O-G cancer care. The audit
included 71% of all patients diagnosed in England
during the audit period.3 This gives a comprehensive
picture on how patients are managed in routine clinical
service and not just the highly selected patient popula-
tion that participates in clinical research. However, the
study has a number of limitations. First, for some patients,
information on performance status and pretreatment
stage was missing. Assuming that data were ‘missing at
random’, we imputed missing data using chained equa-
tions. The estimates derived from this analysis are similar
to those of the complete case analysis, suggesting that the
model results are reliable. However, we cannot exclude
the possibility of residual confounding because factors
such as patients’ psychological characteristics or social
support networks can be important predictors of treat-
ment completion.33 34 A second limitation is that infor-
mation on treatment completion was missing for a
signiﬁcant proportion of patients. The high proportion
of missing data might be related to the administration of
chemotherapy in the outpatient setting, natural disease
progression and patient preferences, all of which contrib-
ute to the difﬁculty in assessing completion rates.
CONCLUSION
We assessed completion of treatment of patients receiv-
ing palliative chemotherapy for oesophageal and gastric
cancer. We found that only 53% of patients completed
their therapy. Key factors predicting non-completion are
patients’ age, performance status and level of depriv-
ation. Elderly patients with incurable O-G cancer who
have poor performance status are unlikely to complete
palliative chemotherapy. Given the toxicity of the treat-
ment, patients’ likelihood to complete and beneﬁt from
Figure 1 Completion of palliative chemotherapy, by age and
performance status (adjusted for sex, deprivation, treatment
stage, location of tumour and comorbidities). ECOG, Eastern
Cooperative Oncology Group.
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treatment should be assessed carefully when deciding on
treatment intent and modality.
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